ASPIRE-Hemophilia Faq

Frequently Asked Questions

What are the ASPIRE HEMOPHILIA Research Awards?
The U.S. Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia to support ongoing basic science and clinical investigation in hemophilia A and B. In an era of increased competition for research funding, the 2016 U.S. ASPIRE Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of hemophilia A and B. The ASPIRE HEMOPHILIA Research Awards Program utilizes an independent, external expert panel to review and rank the successful grant applications. (top)

Who is eligible to apply for ASPIRE HEMOPHILIA Research awards?
To be eligible, applicants must have a professional degree (e.g. MD, PhD, PharmD, etc.) and reside in the United States. Mid-career or Senior Investigators are encouraged to apply; however, in order to stimulate the careers of young investigators, preference will be given to those investigators who are currently conducting postdoctoral PhD research or within 5 years of fellowship completion. Applicants currently enrolled in a residency or fellowship program are not eligible. (top)

What is the role of Pfizer in the ASPIRE HEMOPHILIA Research awards?
While Pfizer will fully fund successful ASPIRE HEMOPHILIA Research Awards, the proposals will be reviewed and ranked by an independent, external expert panel. Pfizer will provide infrastructure and administrative support to facilitate the application and the review process as well as notify applicants and distribute awards. (top)

How many ASPIRE HEMOPHILIA Research Awards are available and what is the monetary amount of each award?
For the 2016 cycle, up to 4 awards will be granted. The amount of each award will be up to approximately $125,000 per year, for up to 2 years, inclusive of institutional overhead (capped at 28%). (top)

What is the deadline for application?
Applications must be received by Monday, 25 April 2016. (top)

When will the ASPIRE HEMOPHILIA Research Awards for 2016 be announced?
The successful awardees will be notified by June 15, 2016. (top)

If my application is successful, when will the funding commence?
Awards will commence on or around November/December 2016, pending receipt of all required documents noted on the application form. Contracts that are unable to be executed by the end of the calendar year are subject to loss of funding. (top)

Will I receive a copy of the Review Committee’s evaluation of my grant proposal?
A summary review of the independent expert review panel’s comments will be provided on request to unsuccessful applicants in order to assist them in further refining their grant proposals for possible future submissions. (top)

Is the funding a per-annum or per-study amount?
Yearly grant monies will be distributed on a per-annum basis. (top)

Does the funding include Institutional overhead costs and indirect costs?
Yes, the funding award includes indirect costs, and institutional overhead costs. Final budgets of those studies awarded a grant will be reviewed for fair market value before the contracting process begins. (top)

What are indirect costs?
Indirect costs are additional study expenses such as costs for publication, IRB/IEC review fees, supplies, software license fees, and travel. (top)

What are institutional overhead costs?
Institutional overhead costs, are costs to the institution for the support of your study. They are not easily identifiable in an economically feasible way as exclusively related to a particular project but are necessary to conduct the grant. Some examples of these costs are human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance. (top)

How are the funds dispersed?
Yearly grant monies will be distributed at 50% at the beginning of the award year and 50% upon a subsequent milestone such as submission of the yearly grant progress/final report. (top)

How may the ASPIRE HEMOPHILIA Research funding be used?
Funds may be used to cover the awardees’ salary and fringe benefits, as well as other direct expenses incurred during the research project. Direct expenses may include the salary of technical associates; the purchase of relevant laboratory supplies; direct expenses necessary for proper conduct of research (e.g. subject-related costs, study-related personnel costs, diagnostic fees/services, data management expenses). Indirect costs may include and travel expenses to scientific meetings, software licensing fees, publication costs etc.

No other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the ASPIRE Program. However, an ASPIRE HEMOPHILIA Research Program grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding. (top)

Can ASPIRE HEMOPHILIA Research Award funding be used to purchase equipment?
No. ASPIRE HEMOPHILIA Research funds may not be used to purchase equipment, although the purchase of relevant laboratory supplies is allowed.(top)

Are the ASPIRE HEMOPHILIA Research awards renewable?
No. Each ASPIRE HEMOPHILIA Research award is a one-time, non-renewable research grant. (top)

Are the ASPIRE HEMOPHILIA Research awards open to researchers working outside the United States?
No. The ASPIRE HEMOPHILIA Research awards are open only to researchers from the United States. (top)

What areas of research meet the criteria for the ASPIRE HEMOPHILIA Research Awards?
Pfizer will consider applications which address one of the following areas in Hemophilia A and/or Hemophilia B. Applications comprising laboratory investigation or clinical research will be considered.

  • Adherence of patients to prescribed regimen
  • Bleeding phenotype, access to care, and social issues concerning hemophilia carriers
  • Epidemiology/burden of disease/outcomes research
  • Imaging of joints, including musculoskeletal ultrasound
  • Impact of physical activity/exercise including coordination of preventative factor regimens
  • Management/phenotype of aging persons with hemophilia
  • Relevance of alternative hemostatic pathways to hemophilia
  • Routine prophylaxis and preventative treatment using standard half-life factor replacement products
  • Significance and location of extravascular coagulation factor stores
  • Surgical prophylaxis using standard half-life factor replacement products
  • Transition issues (adolescent to adult)


Are there any specific research areas that are excluded from ASPIRE HEMOPHILIA Research Awards?
The following topics fall outside of the scope of the ASPIRE HEMOPHILIA Research Program:

  • General education and / or training
  • Public health
  • Support for ongoing clinical programs that are part of an organization’s routine operations.
  • Proposals that do not evaluate Hemophilia A or Hemophilia B (top)

Will non-drug research proposals be considered?
Yes. Both drug and non-drug proposals will be considered for funding. (top)

If the study uses a Pfizer drug, what are Pfizer’s procedures for reporting of Serious Adverse Events?
Reporting of Serious Adverse Events is a key responsibility of the Research Award Principal Investigator. (top)

For All Studies Using a Pfizer Product and/or Device: Pfizer requires that, within 24 hours of first awareness of the event (or immediately if the event is fatal or life-threatening), the principal investigator will report to Pfizer by facsimile any Serious Adverse Event (SAE) that occurs during the SAE reporting period in a study subject assigned to receive the Pfizer Product. In addition, for studies using a Pfizer device or Pfizer product packaged with a device, reportable events include not only SAEs but also Device Incidents and Device Near-Incidents.
  • Reporting Forms: The principal investigator will report such SAEs using the Pfizer IIR SAE reporting form or the approved local regulatory form (i.e., FDA MEDWATCH form, CIOMS, etc.) and the Reportable Event Fax Cover Sheet provided by Pfizer. SAEs should be reported as soon as they are determined to meet the definition, even if complete information is not yet available.
  • Reporting Period: The Reportable Events that are subject to this provision are those that occur from after the first dose of the Pfizer product through 28 days after discontinuation of the Pfizer product.
  • Follow-up Information: The institution and/or principal investigator will assist Pfizer in investigating any SAE and will provide any follow-up information reasonably requested by Pfizer.
  • Regulatory Reporting: Reporting an SAE to Pfizer does not relieve the institution and/or principal investigator of the responsibility for reporting it to the FDA or local regulatory authority, as required. (top)

Can an exception be made for certain applicants regarding the eligibility criteria to the ASPIRE HEMOPHILIA Research awards?
The eligibility requirements have been carefully designed to attract appropriate candidates. In keeping with the purpose and intention of the ASPIRE awards, applicants must meet all the criteria in order to be considered for an award. Submissions outside these parameters will not be considered. (top)

What is the ultimate expectation of projects that receive funding through the ASPIRE HEMOPHILIA Research Awards Program?
Projects are expected to yield results that will advance the medical knowledge of Hemophilia A or Hemophilia B. It is expected that results will be presented at scientific meetings and published in peer-reviewed journals. (top)

I’m still not sure if my proposed research topic meets the criteria, how can I find out?
Please contact the ASPIRE Coordinator with a brief description of your proposed research area.
Email: (top)

Is there a time limit for conducting the funded research?
Interim of final study results are expected before each 31 December commencing the year after the award is made.(top)

How do I apply for a ASPIRE HEMOPHILIA Research Award?
Applications are to be submitted to Pfizer through an online submission website. Visit, and click on “Awards in Hemophilia, United States”, and click on the “Apply” tile in the blue bar at the top of the page. From there you will be routed to Pfizer’s global investigator-initiated research website. Click on “Submit an IIR Request” and follow the online instructions. Applicants must have “ASPIRE-US 2016” included in the Study Title field in the Study Details section of the online submission portal.

Completed application forms must be accompanied by the following documents:

  • Cover letter on institutional letterhead
  • The 3 most relevant articles from the Applicant’s scientific publications (if applicable)
  • An abbreviated curriculum vitae (CV) (limited to 3 pages)
  • Description of available laboratory facilities
  • Listing of other research support available with a description of overlap and, if applicable, a listing of consenting collaborators (including CVs)
  • Bibliography of relevant references
  • Budget for proposed research (top)

What if I don’t fully understand the ASPIRE application process?
Please refer to the application guide. If you still have questions, please email the coordinator at (top)

What do I do if I have a question that is not covered here?
If you require clarification on an issue not addressed here, please contact the ASPIRE Coordinator, (top)

Yes. Therapeutic areas, application dates, deadlines and eligibility vary between programs.
Please visit for more information. (top)

Can I be notified when future ASPIRE competitive grants programs become available?
Visit and complete the contact information section to receive future program notifications. (top)

ASPIRE Hemophilia award winners may apply for awards in the future. Awards are based upon scientific merit commensurate with funding that is available. Please inquire before applying. (top)